Zelda Secures Australian Patent For Novel Prognostic Marker For Breast Cancer
Zelda awarded patent for a novel prognostic biomarker for breast cancer
Builds on Zelda’s world-class intellectual property portfolio for medicinal cannabis and cancer therapy
Prognostic marker helps predict patient survival and the probability of disease recurrence
Complements Zelda’s ongoing programmes to develop cannabis-based therapies for cancer
Patent provides protection until 2038
Zelda Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF): is pleased to announce the grant of a new patent in Australia covering a novel method to predict patient disease-free survival. The patent provides protection until 2038.
The patent (AU2017346940A) entitled “Prognostic method and kits useful in said method” details a method for detecting levels of expression of a novel receptor complex containing HER2 and CB2. HER2 is a well-recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system. Together they form a novel receptor complex that represents a prognostic marker for HER2 positive breast cancer.
Zelda’s Managing Director, Dr Richard Hopkins commented “We’re delighted with the allowance of this patent, which supports Zelda’s strategy of building a world-class intellectual property portfolio and the development of cannabis- based products. Further news is expected as this patent family progresses through the international examination phase.
I’d also like to acknowledge the work of Professor Cristina Sanchez and her team who generated the data that supported this patent. This work was recently published in the prestigious peer-reviewed Proceedings of the National Academy of Sciences. This outcome highlights the benefit of Zelda’s approach of partnering with world-leading cannabis researchers.
Importantly, Professor Sanchez’s discovery of a novel prognostic biomarker, will complement our ongoing efforts develop to cannabis-based medicines to treat breast cancer."
Tim Slate
Company Secretary
